ORPHA:698043
Fibromuscular dysplasia of the renal arteries
Also known as: Renal FMD · Renal artery fibromuscular dysplasia
Publications
335
Trials
1
Interventional, condition-specific
Researchers
1,094
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
How rare: How common this is has not been clearly measured.
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
335 matched papers (152 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
1 matched on ClinicalTrials.gov
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-27
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
335
335 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
335 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
152 in the last 10 years · low confidence
Phrase hits: 335 · MeSH hits: 0
Who's working on it?
1,094
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Persu A11 papers · 2026
Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Papers in Europe PMC - 02
- 03Januszewicz A8 papers · 2022
Department of Hypertension, Institute of Cardiology, Warsaw, Poland.
Papers in Europe PMC - 04Adlam D6 papers · 2022
Department of Cardiovascular Sciences, University of Leicester, NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, United Kingdom.
Papers in Europe PMC - 05Gornik HL6 papers · 2022
1 Division of Cardiovascular Medicine, University Hospitals Cleveland Medical Center and UH Harrington Heart and Vascular Institute, Cleveland, OH, USA.
Papers in Europe PMC - 06Jeunemaitre X6 papers · 2019
17 APHP, Department of Genetics and Centre for Rare Vascular Diseases, Hôpital Européen Georges Pompidou, Paris, France.
Papers in Europe PMC - 07Olin JW6 papers · 2022
Zena and Michael A Wiener Cardiovascular Institute & the Marie-Josée and Henry R Kravis Center for Cardiovascular Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA jeffrey.olin@mountsinai.org.
Papers in Europe PMC - 08Pappaccogli M6 papers · 2024
Division of Cardiology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium.
Papers in Europe PMC - 09Prejbisz A6 papers · 2022
Department of Hypertension, Institute of Cardiology, Warsaw, Poland.
Papers in Europe PMC - 10Touzé E6 papers · 2026
Department of Neurology, Paris Descartes University, Sainte-Anne Hospital, 1, rue Cabanis, 75014 Paris, France; Department of Neurology, University of Caen Basse-Normandie, CHU Côte de Nacre, 14000 Caen, France. Electronic address: emmanuel.touze@unicaen.fr.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
1
interventional trials for this specific condition
1 interventional trial matched this specific condition name; none in our sample are currently recruiting.
Data as of 9 September 2026
1 interventional trial — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 80.1th percentile).
low confidence · 80.1th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
1 interventional trials matched after quoted-phrase search and title/condition post-filter.
No currently recruiting studies in the matched set. Open the same search on ClinicalTrials.gov.
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT06913530·NOT YET RECRUITING·European Multicentre Study of Long-term Results Following Visceral Arteries Revascularization: the E-VisAR Study
Uncertain·Conditions: Visceral Artery Aneurysm · Mesenteric Artery Ischemia · Renal Artery Aneurysm · Renal Artery Stenosis·Matched via name phraseAt least one provider returned uncertain or parent-category.
- NCT05363748·RECRUITING·Renal Artery Fibromuscular Dysplasia Registry
Uncertain·Conditions: Renal Artery Fibromuscular Dysplasia·Matched via name phraseAt least one provider returned uncertain or parent-category.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 21 · after dedupe 21 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 21 · dropped 0 · fetched 2026-07-27
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (21)
- isrctn·ISRCTN24585341·No longer recruiting·Combining maximized ("proximal") brain protection in percutaneous treatment of carotid artery narrowings with stents designed to trap the atherosclerotic plaque: a study of brain injury
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN10201070·No longer recruiting·Study evaluating the effects of GOZEN BIOMATCHA® on vascular health
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN60401373·Recruiting·The Impact of botulinum toxin type A for facial aesthetics on psychological stress and periodontal disease therapy
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN28161621·No longer recruiting·Ketogenic diet and type 2 diabetes
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN92249277·No longer recruiting·New biomarkers of endothelial dysfunction
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN59133298·No longer recruiting·Vascular effects of regular cigarettes versus electronIc cigarettes
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN27860457·No longer recruiting·ON-EPIC Oral nitrate supplementation to enhance pulmonary rehabilitation in chronic obstructive pulmonary disease
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN40476871·No longer recruiting·Does allopurinol reduce thickening of the left ventricle of the heart in patients with treated hypertension?
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN20939990·No longer recruiting·Protective effect of α-Lipoic Acid on the Early stage of Diabetic Nephropathy
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN45316882·No longer recruiting·DRISK Study
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN51279843·No longer recruiting·Efficacy of metformin in pregnant obese women: a randomised controlled trial
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN34097747·No longer recruiting·Effect of clopidogrel and acetylsalicylic acid (ASA) versus clopidogrel or ASA alone on brachial flow mediated vasodilation in patients with coronary artery disease
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN75081811·No longer recruiting·The effects of oral vitamin D supplementation on cardiovascular disease risk in UK South Asian women
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN92186858·No longer recruiting·Vitamin D for Isolated Systolic Hypertension (VitDISH)
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN35143689·No longer recruiting·Candesartan in renal artery stenosis (CARLAS)
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN91419926·No longer recruiting·Adolescent type 1 diabetes cardio-renal intervention trial
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN14741769·No longer recruiting·Effect of 8 weeks oral pentaerithrityltetranitrate on endothelial dysfunction in patients with coronary artery disease: a prospective, randomized, double-blind, placebo-controlled, monocentric clinical trial of phase IV
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN17892444·No longer recruiting·Effect of clopidogrel loading dose on brachial flow mediated vasodilation in patients with coronary artery disease
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN30714266·No longer recruiting·Trial in Rheumatoid Arthritis of Lisinopril
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN48365122·No longer recruiting·Impact of 12 weeks oral niacin on endothelial function, lipid composition and cardiovascular biomarkers in patients with coronary artery disease: a prospective, randomized, double-blind, placebo-controlled,
monocentric clinical trial of phase IV
Uncertain — At least one provider returned uncertain or parent-category.
- isrctn·ISRCTN35570362·No longer recruiting·Subclinical hypothyroidism (SCH), cardiovascular risk and quality of life
Uncertain — At least one provider returned uncertain or parent-category.
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Fibromuscular dysplasia of the renal arteries — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Fibromuscular dysplasia of the renal arteries" OR "Renal FMD" OR "Renal artery fibromuscular dysplasia"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Fibromuscular dysplasia of the renal arteries" OR "Fibromuscular dysplasia of renal arteries" OR "Renal FMD" OR "Renal artery fibromuscular dysplasia"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 1 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- No Orphanet definition and no Mondo IDs — likely taxonomy scaffolding; confidence capped at low
Ingested 2026-07-26T02:09:30.003Z